Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Bactericidal effect of pyridine-2-thiol 1-oxide sodium salt and its complex with iron against resistant clinical isolates of Mycobacterium tuberculosis

Full text
Author(s):
Campos, Debora L. [1] ; Machado, Ignacio [2] ; Ribeiro, Camila M. [1] ; Gambino, Dinorah [3] ; Pavan, Fernando R. [1]
Total Authors: 5
Affiliation:
[1] Sao Paulo State Univ UNESP, Fac Pharmaceut Sci, Dept Biol Sci, Araraquara, SP - Brazil
[2] Univ Republica, Fac Quim, Area Quim Analit, Montevideo - Uruguay
[3] Univ Republica, Fac Quim, Area Quim Inorgan, Montevideo - Uruguay
Total Affiliations: 3
Document type: Journal article
Source: JOURNAL OF ANTIBIOTICS; v. 73, n. 2, p. 120-124, FEB 2020.
Web of Science Citations: 1
Abstract

The objective of this study was to determine the activity of pyridine-2-thiol 1-oxide sodium salt (Na mpo) and its complex with iron {[}Fe(mpo)(3)] against Mycobacterium tuberculosis. The compounds were tested against a standard strain of M. tuberculosis H(37)Rv (ATCC 27294), with minimal inhibitory concentrations (MIC90) of 7.20 and 1.07 mu M to Na mpo and {[}Fe(mpo)(3)], respectively, and against three clinical isolates with different genotypic profiles, with MIC values ranging from 0.74 to 6.52 and 0.30 to 2.25 mu M to Na mpo and {[}Fe(mpo)(3)], respectively. {[}Fe(mpo)(3)] was more effective against susceptible strains but both compounds were effective in inhibiting MDR and XDR-TB clinical strains. The profile activity was determined through the methodology of a time-kill curve against standard and clinical strains of M. tuberculosis. Time-kill studies indicated that Na mpo had an early bactericidal activity against H(37)Rv and clinical isolates, with sterilizing effects observed in 5 and 7 days, respectively, at its MIC90. The anti MDR and XDR-M. tuberculosis activity and bactericidal effect of Na mpo and {[}Fe(mpo)(3)] demonstrate their potential as new compounds for the treatment of tuberculosis. (AU)

FAPESP's process: 18/00163-0 - Development and search of new antimicrobials against Tuberculosis: from screening to pre-clinical studies in vivo
Grantee:Fernando Rogério Pavan
Support Opportunities: Regular Research Grants
FAPESP's process: 13/14957-5 - Research potential against tuberculosis of a new class of furoxan compounds and nanostructured compounds of the ruthenium(II) and copper (II)
Grantee:Fernando Rogério Pavan
Support Opportunities: Research Grants - Young Investigators Grants